Halofenate: effectiveness of two dosage forms and two dose schedules.
作者信息
Hutchison J C, Wilkinson W H
出版信息
Atherosclerosis. 1974 May-Jun;19(3):417-28. doi: 10.1016/s0021-9150(74)80006-7.
PMID:4133379
Abstract
摘要
相似文献
1
Halofenate: effectiveness of two dosage forms and two dose schedules.卤芬酯：两种剂型和两种给药方案的疗效
Atherosclerosis. 1974 May-Jun;19(3):417-28. doi: 10.1016/s0021-9150(74)80006-7.
2
Studies of the uricosuric action of the hypolipidemic drug halofenate.降血脂药物卤芬酯促尿酸排泄作用的研究。
Clin Pharmacol Ther. 1973 Jul-Aug;14(4):547-51. doi: 10.1002/cpt1973144part1547.
3
The metabolic spectrum of halofenate.
Int J Clin Pharmacol Biopharm. 1975 Jul;12(1-2):239-43.
4
One-year trials with halofenate, clofibrate, and placebo.使用卤芬酯、氯贝丁酯和安慰剂进行的为期一年的试验。
Clin Pharmacol Ther. 1976 Mar;19(3):352-9. doi: 10.1002/cpt1976193352.
5
A two-year crossover therapeutic trial with halofenate and clofibrate.
Am J Med Sci. 1976 Nov-Dec;272(3):277-84. doi: 10.1097/00000441-197611000-00005.
6
Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Clin Pharmacol Ther. 1977 Sep;22(3):340-51. doi: 10.1002/cpt1977223340.
7
The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Atherosclerosis. 1973 Nov-Dec;18(3):353-62. doi: 10.1016/0021-9150(73)90065-8.
8
Effect of halofenate on serum uric acid.卤芬酯对血清尿酸的影响。
Clin Pharmacol Ther. 1973 May-Jun;14(3):371-3. doi: 10.1002/cpt1973143371.
9
Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
S Afr Med J. 1977 Mar 12;51(11):348-52.
10
[Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Arzneimittelforschung. 1976;26(12):2221-4.
Zotero 插件